The maintenance therapy by Gemcitabine after the Gemcitabine(GEM)+Cisplatin (CDDP) combined therapy over a postoperative recurrence / advanced biliary tract cancer:a phase II, multicenter study
Not Applicable
Recruiting
- Conditions
- biliary tract cancer
- Registration Number
- JPRN-UMIN000012983
- Lead Sponsor
- Kawasaki Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with an active concomitant malignancy 2) Patients with a previous history of a severe drug hypersensitivity 3) Patients with severe comobidities (pulmonary fibrosis or interstitial pneumonia, cardiovascular failure, renal failure, hepatic failure, hemorrhagic digestive ulcer, and gastrointestinal bleeding, intestinal tract paralysis, ileus, uncontrollable diabetes ). 4) Patients with an active concomitant infection 5) Pregnant, lactating female and patients of reproductive potential who did not use effective contraception 6) Patients with a severe mental disorder 7) Inappropriate patients for entry on this study in the judgement of the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method